PURA reported over one hundred percent (100%) revenue growth year-to-date through the period ended September 30, 2019 compared to the same period in the previous year, 2018.
DALLAS, Nov. 21, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE – Puration, Inc. (USOTC: PURA) today announced a scheduled management update to be published next week on Tuesday, November 26, 2019, to review the recent financial reported filed with OTC Markets for the period ended September 30, 2019.
The update will include the latest on management’s $4 million 2019 revenue target and plans for reaching $8 million in 2020.
PURA reported over one hundred percent (100%) revenue growth year-to-date through the period ended September 30, 2019, compared to the same period in the previous year, 2018.
PURA reported $1,895,000 in revenue for the period ending September 30, 2019, and a twelve percent (12%) net profit at $232,500.
The company has recently announced major new distribution agreements with initial orders commencing in the fourth quarter of 2019 and management maintains its $4 million 2019 revenue target.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.